TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B

Thermo Fisher Scientific operating income 1985–2026

Thermo Fisher Scientific's operating income in Q3 FY2026, the three months to 26 September 2026, was 2.26B USD, up 9.1% on the same quarter a year before. Thermo Fisher Scientific's operating income over the last twelve months was 8.52B USD, up 5.1% on the twelve months before. In fiscal year 2025 it was 8.11B USD, up 5.8% on the year before.

Last updated 3 Nov 2026 · Next report 4 Feb 2027

Operating income

Operating income · +12.5% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM26 Sept 20268.52B+5.12%17.98%19.62B41.44%11.24B
FY202531 Dec 20258.11B+5.83%18.20%18.24B40.93%11.47B
FY202431 Dec 20247.66B+2.90%17.87%17.73B41.34%11.80B
FY202331 Dec 20237.45B-12.66%17.37%17.19B40.12%11.20B
FY202231 Dec 20228.53B-17.38%18.98%19.01B42.33%11.94B
FY202131 Dec 202110.32B+30.66%26.31%19.63B50.07%11.97B
FY202031 Dec 20207.90B+85.42%24.51%16.03B49.75%10.11B
FY201931 Dec 20194.26B+9.99%16.67%11.34B44.41%7.02B
FY201831 Dec 20183.87B+18.52%15.90%10.99B45.11%6.20B
FY201731 Dec 20173.27B+14.27%15.62%9.68B46.27%5.05B
FY201631 Dec 20162.86B+14.61%15.64%8.58B46.96%4.25B
FY201531 Dec 20152.49B+6.22%14.70%7.84B46.20%4.04B
FY201431 Dec 20142.35B+30.56%13.90%7.89B46.69%4.25B
FY201331 Dec 20131.80B+10.40%13.74%5.63B42.98%2.58B
FY201231 Dec 20121.63B+9.98%13.02%5.41B43.28%2.49B
FY201131 Dec 20111.48B+17.15%12.63%4.87B41.50%2.18B
FY201031 Dec 20101.26B+13.11%11.72%4.27B39.62%1.92B
FY200931 Dec 20091.12B-11.72%11.06%4.07B40.26%1.83B
FY200831 Dec 20081.27B+18.81%12.06%4.24B40.41%2.07B
FY200731 Dec 20071.07B+191.76%10.94%3.89B39.95%1.78B
FY200631 Dec 2006365.30M+24.35%9.63%1.69B44.49%502.07M
FY200531 Dec 2005293.77M+15.46%11.16%1.24B47.00%435.89M
FY200431 Dec 2004254.44M+37.70%11.53%1.02B46.04%336.34M
FY200331 Dec 2003184.77M+18.86%8.81%948.02M45.21%279.30M
FY200231 Dec 2002155.45M+354.51%7.45%927.38M44.45%193.08M
FY200131 Dec 200134.20M-82.74%1.56%958.62M43.81%265.43M
FY200031 Dec 2000198.16M-20.29%8.69%1.02B44.81%295.65M
FY199931 Dec 1999248.60M-33.85%10.06%1.21B48.81%362.20M
FY199831 Dec 1998375.80M-7.67%9.72%1.84B47.65%353.40M
FY199731 Dec 1997407.00M+43.21%11.44%1.72B48.36%371.60M
FY199631 Dec 1996284.20M+14.92%9.69%1.39B47.40%399.40M
FY199531 Dec 1995247.30M+37.54%11.20%1.08B49.05%332.30M
FY199431 Dec 1994179.80M+45.47%11.34%719.00M45.35%242.10M
FY199331 Dec 1993123.60M+80.97%9.89%536.60M42.94%166.00M
FY199231 Dec 199268.30M+78.33%7.20%369.20M38.90%97.50M
FY199131 Dec 199138.30M+7.58%4.75%295.30M36.66%61.70M
FY199031 Dec 199035.60M+100.00%5.03%265.00M37.43%54.40M
FY198931 Dec 198917.80M-7.29%3.07%194.90M33.66%30.50M
FY198831 Dec 198819.20M+156.00%3.84%174.90M34.94%30.30M
FY198731 Dec 19877.50M-39.02%1.96%134.70M35.13%17.60M
FY198631 Dec 198612.30M+151.02%3.71%112.30M33.87%20.70M
FY198531 Dec 19854.90M—1.84%91.40M34.40%12.70M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Thermo Fisher Scientific's operating income

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.